In the past week, PHAT stock has gone down by -8.33%, with a monthly decline of -20.19% and a quarterly plunge of -42.76%. The volatility ratio for the week is 16.22%, and the volatility levels for the last 30 days are 9.09% for Phathom Pharmaceuticals Inc The simple moving average for the past 20 days is -9.55% for PHAT’s stock, with a -55.18% simple moving average for the past 200 days.
Is It Worth Investing in Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Right Now?
PHAT has 36-month beta value of 0.40. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PHAT is 38.64M, and currently, short sellers hold a 38.46% ratio of that float. The average trading volume of PHAT on March 10, 2025 was 1.03M shares.
PHAT) stock’s latest price update
The stock of Phathom Pharmaceuticals Inc (NASDAQ: PHAT) has decreased by -14.24 when compared to last closing price of 5.90.Despite this, the company has seen a loss of -8.33% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-06 that Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Eric Sciorilli – Head, Investor Relations Terrie Curran – President & Chief Executive Officer Martin Gilligan – Chief Commercial Officer Molly Henderson – Chief Financial Officer Conference Call Participants Yatin Suneja – Guggenheim Joseph Stringer – Needham Annabel Samimy – Stifel Kristen Kluska – Cantor Fitzgerald Paul Choi – Goldman Sachs Matthew Caufield – H.C. Wainwright Operator Hello, and welcome to the Phathom Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Results Call.
Analysts’ Opinion of PHAT
Many brokerage firms have already submitted their reports for PHAT stocks, with Cantor Fitzgerald repeating the rating for PHAT by listing it as a “Overweight.” The predicted price for PHAT in the upcoming period, according to Cantor Fitzgerald is $23 based on the research report published on February 14, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see PHAT reach a price target of $24. The rating they have provided for PHAT stocks is “Buy” according to the report published on May 03rd, 2024.
Needham gave a rating of “Buy” to PHAT, setting the target price at $26 in the report published on January 05th of the previous year.
PHAT Trading at -21.21% from the 50-Day Moving Average
After a stumble in the market that brought PHAT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.33% of loss for the given period.
Volatility was left at 9.09%, however, over the last 30 days, the volatility rate increased by 16.22%, as shares sank -14.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.08% lower at present.
During the last 5 trading sessions, PHAT fell by -8.33%, which changed the moving average for the period of 200-days by -51.99% in comparison to the 20-day moving average, which settled at $5.59. In addition, Phathom Pharmaceuticals Inc saw -37.68% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHAT starting from Henderson Molly, who sale 6,583 shares at the price of $6.59 back on Jan 21 ’25. After this action, Henderson Molly now owns 93,546 shares of Phathom Pharmaceuticals Inc, valued at $43,371 using the latest closing price.
Nabulsi Azmi, the Chief Operating Officer of Phathom Pharmaceuticals Inc, sale 7,886 shares at $6.59 during a trade that took place back on Jan 21 ’25, which means that Nabulsi Azmi is holding 233,390 shares at $51,957 based on the most recent closing price.
Stock Fundamentals for PHAT
Current profitability levels for the company are sitting at:
- -5.02 for the present operating margin
- 0.86 for the gross margin
The net margin for Phathom Pharmaceuticals Inc stands at -6.05. The total capital return value is set at -0.95.
Based on Phathom Pharmaceuticals Inc (PHAT), the company’s capital structure generated -3.91 points at debt to capital in total, while cash flow to debt ratio is standing at -1.32. The debt to equity ratio resting at -0.8. The interest coverage ratio of the stock is -3.85.
Currently, EBITDA for the company is -261.52 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 4.65. The receivables turnover for the company is 1.42for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.20.
Conclusion
To put it simply, Phathom Pharmaceuticals Inc (PHAT) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
